Filing Flows › Health Care › Aspira Women's Health (AWHL)
Aspira Women's Health (AWHL) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Aspira Women's Health (AWHL) Q2 2026 earnings results →
Q2 2026 Revenue down 15% year over year to $2.0M · 118¢ of every $1 of revenue lost · operating margin -89.7%
Aspira Women's Health made $2.0M in Q2 2026 (-15% Y/Y). Operating margin -89.7%, net loss $2.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $2.0M in Q2 2026, down 15% year over year and up 4% from the previous quarter.
Gross margin was 55.3%, down 8.5 points from Q2 2025. Operating costs exceeded revenue by $1.8M, an operating margin of -89.7%. Operating expenses fell 11% while revenue fell 15%. The quarter ended with a net loss of $2.4M, after a profit of $676K the previous quarter.
Operating cash flow was −$2.0M. Non-cash charges added back $40K of depreciation and amortization and $19K of share-based compensation. Working capital and other items added $351K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $2.0M | -15% | -89.7% | −$2.4M | −$2.0M |
| Q1 2026 | 10-Q | May 15, 2026 | $2.0M | -14% | -112.0% | $676K | −$359K |
| Q4 2025 | 10-K | Apr 1, 2026 | $2.2M | -5% | -57.6% | −$3.4M | −$2.0M |
| Q3 2025 | 10-Q | Nov 14, 2025 | $2.3M | +2% | -68.5% | −$4.9M | −$212K |
| Q2 2025 | 10-Q | Aug 13, 2025 | $2.4M | -0.8% | -75.3% | −$2.7M | −$1.7M |
| Q4 2024 | 10-K | Mar 27, 2025 | $2.3M | -97% | -146.1% | −$1.4M | −$1.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Aspira Women's Health
Aspira Women’s Health Inc. (“Aspira” and its wholly-owned subsidiaries are collectively referred to as the “Company”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company currently markets and sells the following products and related services: (1) the Ova1Plus workflow, which uses Ova1, a qualitative serum test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician’s independent clinical and radiological evaluation does not indicate malignancy, as the primary test and Overa, a second-generation biomarker test intended to maintain Ova1’s high sensitivity while improving specificity, as a reflex for Ova1 intermediate range results, leveraging the strengths of Ova1’s MIA sensitivity and…
In its own words, from its 10-Q, filed Aug 14, 2026.
Aspira Women's Health against its In Vitro & In Vivo Diagnostic Substances peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -15% against the peers' median +2%. Operating margin: -89.7% against the peers' median -1.2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| AWHL Aspira Women's Health | Q2 2026 | $2.0M | -15% | -89.7% |
| IDXX Idexx Laboratories | Q3 2026 | $1.2B | +10% | 33.1% |
| QDEL QuidelOrtho | Q3 2026 | $619M | -12% | -1.2% |
| LNTH Lantheus Holdings | Q3 2026 | $390M | +2% | 8.3% |
| NEOG Neogen | Q1 FY27 | $223M | +6% | -0.8% |
| MYGN Myriad Genetics | Q3 2026 | $203M | -2% | -19.7% |
| TKNO Alpha Teknova | Q3 2026 | $12.7M | +22% | -25.2% |
| ICCC Immucell | Q2 2026 | $7.2M | +12% | 26.9% |
| NTLA Intellia Therapeutics | Q3 2026 | $7.2M | -48% | n/m |
Source: Aspira Women's Health 10-Q on SEC EDGAR · CIK 926617 · In Vitro & In Vivo Diagnostic Substances
13F: who owns AWHL and who is buying
More on AWHL
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q4 2024 results
Compare AWHL with
- Aspira Women's Health vs Alpha Teknova (AWHL vs TKNO)
- Aspira Women's Health vs Immucell (AWHL vs ICCC)
- Aspira Women's Health vs Intellia Therapeutics (AWHL vs NTLA)
- Aspira Women's Health vs Biomerica (AWHL vs BMRA)
- Aspira Women's Health vs Volitionrx (AWHL vs VNRX)
- Aspira Women's Health vs Insight Molecular Diagnostics (AWHL vs IMDX)